The transcriptional repressor Snail promotes mammary tumor recurrence

Cancer Cell

Volumn 8, Issue 3, 2005, Pages 197-209

  Moody, Susan E ^a   Perez, Denise ^a   Pan, Tien Chi ^a   Sarkisian, Christopher J ^a   Portocarrero, Carla P ^a   Sterner, Christopher J ^a   Notorfrancesco, Kathleen L ^a   Cardiff, Robert D ^b   Chodosh, Lewis A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR SNAIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; EPITHELIUM CELL; GENE EXPRESSION; GENE REPRESSION; IN VIVO STUDY; MESENCHYME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL; UPREGULATION;

GASTROPODA; MUS MUSCULUS;

EID: 24944450362     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.07.009     Document Type: Article

References (47)

1. R.E. Bachelder, S.O. Yoon, C. Franci, A.G. de Herreros, and A.M. Mercurio Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implication for the epithelial-mesenchymal transition J. Cell Biol. 168 2005 29 33
2. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, and J. Moore Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J. Clin. Oncol. 14 1996 737 744
3. E. Batlle, E. Sancho, C. Franci, D. Dominguez, M. Monfar, J. Baulida, and A. Garcia De Herreros The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells Nat. Cell Biol. 2 2000 84 89
4. M.S. Berger, G.W. Locher, S. Saurer, W.J. Gullick, M.D. Waterfield, B. Groner, and N.E. Hynes Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading Cancer Res. 48 1988 1238 1243
5. M.J. Blanco, G. Moreno-Bueno, D. Sarrio, A. Locascio, A. Cano, J. Palacios, and M.A. Nieto Correlation of Snail expression with histological grade and lymph node status in breast carcinomas Oncogene 21 2002 3241 3246
6. A. Cano, M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. del Barrio, F. Portillo, and M.A. Nieto The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression Nat. Cell Biol. 2 2000 76 83
7. R.D. Cardiff, E. Sinn, W. Muller, and P. Leder Transgenic oncogene mice. Tumor phenotype predicts genotype Am. J. Pathol. 139 1991 495 501
8. C.L. Carter, C. Allen, and D.E. Henson Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 1989 181 187
9. E.A. Carver, R. Jiang, Y. Lan, K.F. Oram, and T. Gridley The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition Mol. Cell. Biol. 21 2001 8184 8188
10. C.W. Cheng, P.E. Wu, J.C. Yu, C.S. Huang, C.T. Yue, C.W. Wu, and C.Y. Shen Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene Oncogene 20 2001 3814 3823
11. R. Demicheli, G. Bonadonna, W.J. Hrushesky, M.W. Retsky, and P. Valagussa Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour Breast Cancer Res. 6 2004 R689 R696
12. T. Doyle, D.J. Schultz, C. Peters, E. Harris, and L.J. Solin Long-term results of local recurrence after breast conservation treatment for invasive breast cancer Int. J. Radiat. Oncol. Biol. Phys. 51 2001 74 80
13. F.J. Esteva, and G.N. Hortobagyi Prognostic molecular markers in early breast cancer Breast Cancer Res. 6 2004 109 118
14. B. Fisher, S. Anderson, E.R. Fisher, C. Redmond, D.L. Wickerham, N. Wolmark, E.P. Mamounas, M. Deutsch, and R. Margolese Significance of ipsilateral breast tumour recurrence after lumpectomy Lancet 338 1991 327 331
15. B. Fisher, J.H. Jeong, J. Bryant, S. Anderson, J. Dignam, E.R. Fisher, and N. Wolmark Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Lancet 364 2004 858 868
16. A. Fortin, M. Larochelle, J. Laverdiere, S. Lavertu, and D. Tremblay Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy J. Clin. Oncol. 17 1999 101 109
17. I.B. Fuchs, W. Lichtenegger, H. Buehler, W. Henrich, H. Stein, A. Kleine-Tebbe, and G. Schaller The prognostic significance of epithelial-mesenchymal transition in breast cancer Anticancer Res. 22 2002 3415 3419
18. C. Gamallo, J. Palacios, A. Suarez, A. Pizarro, P. Navarro, M. Quintanilla, and A. Cano Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma Am. J. Pathol. 142 1993 987 993
19. Y. Grau, C. Carteret, and P. Simpson Mutations and chromosomal rearrangements affecting the expression of snail, a gene involved in embryonic patterning in Drosophila melanogaster Genetics 108 1984 347 360
20. E.J. Gunther, G.K. Belka, G.B. Wertheim, J. Wang, J.L. Hartman, R.B. Boxer, and L.A. Chodosh A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology FASEB J. 16 2002 283 292
21. N. Guriec, L. Marcellin, B. Gairard, H. Calderoli, A. Wilk, R. Renaud, J.P. Bergerat, and F. Oberling E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival Invasion Metastasis 16 1996 19 26
22. K.M. Hajra, D.Y. Chen, and E.R. Fearon The SLUG zinc-finger protein represses E-cadherin in breast cancer Cancer Res. 62 2002 1613 1618
23. R. Heimann, F. Lan, R. McBride, and S. Hellman Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin Cancer Res. 60 2000 298 304
24. G.N. Hortobagyi Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer Semin. Oncol. 28 2001 43 47
25. X.J. Ma, Z. Wang, P.D. Ryan, S.J. Isakoff, A. Barmettler, A. Fuller, B. Muir, G. Mohapatra, R. Salunga, and J.T. Tuggle A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 2004 607 616
26. S.E. Moody, C.J. Sarkisian, K.T. Hahn, E.J. Gunther, S. Pickup, K.D. Dugan, N. Innocent, R.D. Cardiff, M.D. Schnall, and L.A. Chodosh Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis Cancer Cell 2 2002 451 461
27. S.R. Niveditha, and P. Bajaj Vimentin expression in breast carcinomas Indian J. Pathol. Microbiol. 46 2003 579 584
28. K. Pantel, V. Muller, M. Auer, N. Nusser, N. Harbeck, and S. Braun Detection and clinical implications of early systemic tumor cell dissemination in breast cancer Clin. Cancer Res. 9 2003 6326 6334
29. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J. Clin. 55 2005 74 108
30. T. Saphner, D.C. Tormey, and R. Gray Annual hazard rates of recurrence for breast cancer after primary therapy J. Clin. Oncol. 14 1996 2738 2746
31. C.M. Schlotter, U. Vogt, U. Bosse, B. Mersch, and K. Wassmann c-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer Breast Cancer Res. 5 2003 R30 R36
32. C. Schmoor, W. Sauerbrei, G. Bastert, and M. Schumacher Role of isolated locoregional recurrence of breast cancer: results of four prospective studies J. Clin. Oncol. 18 2000 1696 1708
33. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
34. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, and M. Pegram Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
35. K. Soo, M.P. O'Rourke, P.L. Khoo, K.A. Steiner, N. Wong, R.R. Behringer, and P.P. Tam Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo Dev. Biol. 247 2002 251 270
36. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, and S.S. Jeffrey Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc. Natl. Acad. Sci. USA 98 2001 10869 10874
37. T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, and S. Geisler Repeated observation of breast tumor subtypes in independent gene expression data sets Proc. Natl. Acad. Sci. USA 100 2003 8418 8423
38. Y. Tang, H. Zhou, A. Chen, R.N. Pittman, and J. Field The Akt proto-oncogene links Ras to Pak and cell survival signals J. Biol. Chem. 275 2000 9106 9109
39. P. Valagussa, G. Bonadonna, and U. Veronesi Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients Cancer 41 1978 1170 1178
40. L.J. van't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, and A.T. Witteveen Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
41. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, and M. Burchmore Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726
42. S.C. Wang, L. Zhang, G.N. Hortobagyi, and M.C. Hung Targeting HER2: recent developments and future directions for breast cancer patients Semin. Oncol. 28 2001 21 29
43. Y. Wang, J.G. Klijn, Y. Zhang, A.M. Sieuwerts, M.P. Look, F. Yang, D. Talantov, M. Timmermans, M.E. Meijer-van Gelder, and J. Yu Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 2005 671 679
44. R.B. Weiss, S.H. Woolf, E. Demakos, J.F. Holland, D.A. Berry, G. Falkson, C.T. Cirrincione, A. Robbins, S. Bothun, I.C. Henderson, and L. Norton Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B J. Clin. Oncol. 21 2003 1825 1835
45. J. Yang, S.A. Mani, J.L. Donaher, S. Ramaswamy, R.A. Itzykson, C. Come, P. Savagner, I. Gitelman, A. Richardson, and R.A. Weinberg Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 117 2004 927 939
46. Z. Yang, S. Rayala, D. Nguyen, R.K. Vadlamudi, S. Chen, and R. Kumar Pak1 phosphorylation of Snail, a master regulator of epithelial-to-mesenchymal transition, modulates Snail's subcellular localization and function Cancer Res. 65 2005 3179 3184
47. B.P. Zhou, J. Deng, W. Xia, J. Xu, Y.M. Li, M. Gunduz, and M.C. Hung Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition Nat. Cell Biol. 6 2004 931 940